Skip to content
lifestyle.phenomena.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Eupraxia Pharmaceuticals Inc.
Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW)
May 5, 2026
Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer
May 1, 2026
Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting
April 22, 2026
Eupraxia Pharmaceuticals Reports Positive Nine-Month Tissue Health and Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis
April 21, 2026
Eupraxia Pharmaceuticals to Present at Upcoming Investor Conferences
April 13, 2026
Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis
March 17, 2026
←
Previous Page
1
2